Logo

ABEO

Abeona Therapeutics Inc.

ABEO

Abeona Therapeutics Inc. • NASDAQ
$5.07 ▼ -1.55% (-0.08)
Market Cap $253.50 M
52w High $7.54
52w Low $3.93
Dividend Yield 0%
P/E 4.19
Volume 392.26K
Outstanding Shares 50.00M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 ▼ $23.53M ▲ $-5.161M ▼ 0% ▼ $-0.1 ▼ $-18.569M ▼
Q2-2025 $400K ▲ $23.092M ▲ $108.833M ▲ 27.208K% ▲ $2.07 ▲ $126.07M ▲
Q1-2025 $0 $19.727M ▲ $-12.029M ▼ 0% $-0.24 ▼ $-10.216M ▼
Q4-2024 $0 $15.896M ▲ $-9.293M ▲ 0% $-0.23 ▲ $-7.437M ▲
Q3-2024 $0 $15.345M $-30.269M 0% $-0.63 $-28.445M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $207.455M ▼ $231.095M ▼ $59.862M ▼ $171.233M ▲
Q2-2025 $225.518M ▲ $246.233M ▲ $82.657M ▲ $163.576M ▲
Q1-2025 $84.155M ▼ $99.364M ▼ $57.968M ▼ $41.396M ▼
Q4-2024 $97.72M ▼ $108.931M ▼ $64.9M ▼ $44.031M ▼
Q3-2024 $109.701M $120.592M $74.819M $45.773M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-5.161M ▼ $-21.187M ▼ $-64.627M ▼ $5.163M ▼ $-80.651M ▼ $-23.707M ▼
Q2-2025 $108.833M ▲ $-18.784M ▼ $155.888M ▲ $10.495M ▲ $147.599M ▲ $-21.685M ▼
Q1-2025 $-12.029M ▼ $-18.402M ▼ $4.213M ▼ $6.768M ▲ $-7.421M ▼ $-19.803M ▼
Q4-2024 $-9.293M ▲ $-16.559M ▼ $18.876M ▲ $5.314M ▲ $7.631M ▲ $-17.165M ▼
Q3-2024 $-30.269M $-12.234M $-6.167M $-299K $-18.7M $-12.638M

Revenue by Products

Product Q2-2018Q3-2018Q4-2018
Grant
Grant
 $0 ▲$0 ▲$0 ▲
Royalty
Royalty
 $0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Abeona is still essentially a pre‑revenue biotech story. Over the past several years it has had almost no product sales and has consistently reported losses. The size of those losses has narrowed somewhat, which suggests better cost control, but expenses still clearly outweigh income. Earnings per share look very volatile largely because of repeated reverse stock splits, not because the underlying business has suddenly swung up or down. Overall, the income statement shows a company in investment mode: high R&D and operating costs, with the hope that commercialization of its new therapy eventually changes that picture.

Balance Sheet

Balance Sheet The balance sheet in the historical data looks very small and quite thin, with limited assets, modest cash, and only a small equity cushion. Debt appears present but not heavy. The narrative around the sale of the Priority Review Voucher points to a much stronger cash position more recently than the raw five‑year table suggests, giving the company a multi‑year operating runway. Even so, this is still a small biotech balance sheet: sensitive to setbacks and likely dependent over time on either product success, new partnerships, or fresh capital to stay well funded.

Cash Flow

Cash Flow Cash flows are consistently negative, driven by operating losses and ongoing development spending. There is essentially no capital spending, so cash burn mainly reflects salaries, trials, manufacturing scale‑up, and overhead. Free cash flow trends match operating cash flow, which underscores that the business is not yet self‑funding. Historically, Abeona has relied on equity raises, partnership deals, and one‑off items like the PRV sale to cover this burn. Future cash flow will depend heavily on how quickly and smoothly ZEVASKYN ramps and whether additional pipeline programs move into later‑stage trials.

Competitive Edge

Competitive Edge Abeona is operating in a focused niche within gene and cell therapy, targeting rare and ultra‑rare diseases where competition is thinner but scientific and regulatory hurdles are high. Its main strengths are an approved, highly specialized cell‑based therapy for a severe skin disease, orphan and rare‑disease regulatory protections, and in‑house manufacturing that many peers lack. The AIM capsid platform adds another layer of differentiation in eye diseases. On the risk side, the company is small compared with larger biotech and pharma players, faces at least one notable competitor in its main disease area, and must still prove that doctors, treatment centers, and insurers will adopt and pay for its therapy at scale.

Innovation and R&D

Innovation and R&D Innovation is clearly Abeona’s core asset. It combines two advanced gene‑therapy approaches: viral vectors for in‑body gene delivery and retroviral methods for modifying a patient’s own cells outside the body. The AIM capsid library gives it a potentially more precise and flexible way to target tissues, especially in the eye, and has been attractive enough to draw outside licensing interest. The ophthalmic pipeline is early but strategically promising, and prior out‑licensing of a program to a larger partner shows it can monetize assets beyond its own commercialization capacity. The main R&D risks are the usual ones in biotech: technical failure, regulatory delays, and the fact that success currently hinges on a relatively small number of key programs.

Summary

Overall, Abeona looks like a high‑science, early commercial‑stage biotech with meaningful upside potential but typical small‑cap biotech risks. Financial statements show a company still living on investment and external funding rather than recurring revenue, though the PRV sale appears to have eased near‑term pressure. Strategically, it benefits from a first‑in‑class approved therapy in a serious rare disease, regulatory exclusivity, and proprietary technology platforms that support a broader pipeline and partnerships. The big variables to watch are how well the ZEVASKYN launch goes, how payers respond on pricing and reimbursement, how quickly the eye‑disease programs advance, and how carefully management manages cash as the company moves from pure R&D into full commercial execution.

NEWS

November 12, 2025 · 7:30 AM UTC

Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates

Read more

November 7, 2025 · 7:30 AM UTC

Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation

Read more

November 3, 2025 · 7:30 AM UTC

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more

October 30, 2025 · 10:45 AM UTC

Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)

Read more

October 20, 2025 · 8:30 AM UTC

Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs

Read more